A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes everything about how it is formulated, stored and assayed - a frequent source of confusion here.
Details up front: a GLP-1 receptor agonist · SURMOUNT-4. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like…
The case in front of me: REDEFINE-1 · tirzepatide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
Details up front: PIONEER-1 · retatrutide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence…
Stated plainly: TRIUMPH-3 · mazdutide. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…
What I have: SUSTAIN-6 · dulaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
Orforglipron is described as a non-peptide oral GLP-1 receptor agonist, which I take to mean it is a conventional small molecule rather than a peptide with a delivery…
Numbers first: mazdutide · SURMOUNT-4. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring answer. I would…
Scale weight, waist circumference and a repetition maximum, all logged weekly. I want to know whether this is a real physical effect or an artefact of how it is…
I would like to know how much of this is established and how much is a reasonable story. I want to know what the trade-off actually is rather than which option is…
What I am working with: dulaglutide · ESSENCE. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows, I would rather…
What I have: SELECT · dulaglutide. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
Conditions: survodutide · ATTAIN-1. I want to know whether this is a real physical effect or an artefact of how it is measured. What prompted the question is an…
The particulars: liraglutide · SURMOUNT-5. I understand the observation; what I do not understand is the mechanism behind it. I have read the two review articles that…
It has now persisted for three weeks, which is what moved this from tolerable to worth asking about. I would like the mechanism, because I want to be able to reason…
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse results